No Data
No Data
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People With Multiple Myeloma Preparing for Stem Cell Collection
JonesTrading Initiates BioLineRx at Buy With $2 Price Target
JonesTrading Initiates BioLine Rx(BLRX.US) With Buy Rating, Announces Target Price $2
JonesTrading analyst Justin Walsh initiates coverage on $BioLine Rx(BLRX.US)$ with a buy rating, and sets the target price at $2.According to TipRanks data, the analyst has a success rate of 33.7%
Buy Rating Affirmed for Bioline RX Ltd on FDA Approval and Market Expansion Potential
ADRs End Higher; Yunji Inc. Climbs 38%
BioLineRx Shares Are Trading Lower. The Company Reported Q2 Financial Results.